Alvotech公司宣布，美国食品药品监督管理局（FDA）已正式受理其生物制品许可申请（BLA），该申请针对的是其拟议产品Avt16。Avt16是一种旨在与Entyvio®进行互换的生物类似药。
Alvotech公司宣布，美国食品药品监督管理局（FDA）已正式受理其生物制品许可申请（BLA），该申请针对的是其拟议产品Avt16。Avt16是一种旨在与Entyvio®进行互换的生物类似药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.